Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yu-Xiao Yang, MD, MSCE, James D. Lewis, MD, MSCE, Solomon Epstein, MD, David C. Metz, MD
Author Affiliations: Division of Gastroenterology (Drs Yang, Lewis, and Metz), Center for Clinical Epidemiology and Biostatistics (Drs Yang and Lewis), Department of Biostatistics and Epidemiology (Drs Yang and Lewis), and Division of Endocrinology (Dr Epstein), University of Pennsylvania School of Medicine, Philadelphia; and Department of Medicine, Doylestown Hospital Research Center, Doylestown, Pa (Dr Epstein).
Corresponding Author: Yu-Xiao Yang, MD, MSCE, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 722 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104 (email@example.com).
"In summary, we observed that PPI therapy is associated with a significantly increased risk of hip fractures, with the highest risk seen among those receiving high-dose PPI therapy. Osteoporotic fractures are common among the elderly population, and they entail considerable morbidity and mortality. On the other hand, PPI therapy is widespread and may have an exaggerated effect among those at risk for osteoporosis..... Controlling only for the matching variables, the crude OR for hip fracture
associated with more than 1 year of PPI therapy was 1.82.... In a separate secondary case-control analysis, long-term PPI therapy was associated with a higher fracture risk (AOR for >1 year of cumulative use, 1.34..... The risk of hip fracture was markedly increased among long-term users of high-dose PPI therapy compared with acid suppression nonusers (AOR, 2.65.....The positive association between long-term PPI therapy and hip fracture was stronger in men (OR, 1.78; 95% CI, 1.42-2.22) than women (OR,
1.36.... The multivariable AOR associated with high-dose long-term PPI therapy was 3.49"
Context Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps.
Objective To determine the association between PPI therapy and risk of hip fracture.
Design, Setting, and Patients A nested case-control study was conducted using the General Practice Research Database (1987-2003), which contains information on patients in the United Kingdom. The study cohort consisted of users of PPI therapy and nonusers of acid suppression drugs who were older than 50 years. Cases included all patients with an incident hip fracture. Controls were selected using incidence density sampling, matched for sex, index date, year of birth, and both calendar period and duration of up-to-standard follow-up before the index date. For comparison purposes, a similar nested case-control analysis for histamine 2 receptor antagonists was performed.
Main Outcome Measure The risk of hip fractures associated with PPI use.
There were 13 556 hip fracture cases and 135 386 controls. The adjusted odds ratio (AOR) for hip fracture associated with more than 1 year of PPI therapy was 1.44 (95% confidence interval [CI], 1.30-1.59). The risk of hip fracture was significantly increased among patients prescribed long-term high-dose PPIs (AOR, 2.65; 95% CI, 1.80-3.90; P .001). The strength of the association increased with increasing duration of PPI therapy (AOR for 1 year, 1.22 [95% CI, 1.15-1.30]; 2 years, 1.41 [95% CI, 1.28-1.56]; 3 years, 1.54 [95% CI, 1.37-1.73]; and 4 years, 1.59 [95% CI, 1.39-1.80]; P .001 for all comparisons).
Conclusion Long-term PPI therapy, particularly at high doses, is associated with an increased risk of hip fracture.
MORE THAN 47 000 HIPfractures occur annually in the United Kingdom.1
Hip fracture is the main manifestation of senile osteoporosis, which results from secondary hyperparathyroidism associated with calcium malabsorption, low calcium intake, and other factors.2 Among the various forms of low-trauma fractures, hip fracture leads to the most devastating consequences.
The mortality rate during the first year after a hip fracture is 20%.3,4 Among those who survived this period, 1 in 5 requires nursing home care.5 In addition, hip fractures invariably require an emergency department visit, hospitalization, surgery, and rehabilitation, incurring huge health care costs.
The advent of potent acid suppressive medications such as proton pump inhibitors (PPIs) has revolutionized the management of acid-related diseases such as gastroesophageal reflux disease (GERD). Millions of individuals have
been using these medications on a continuous or long-term basis.6 Significant
hypochlorhydria, particularly among the elderly population who may have decreased PPI clearance and may be more likely to have hypochlorhydria at baseline due to higher prevalence of Helicobacter pylori infection,7,8 could theoretically result in calcium malabsorption.9,10 In fact, limited animal and human studies have shown that PPI therapy may decrease insoluble calcium absorption or bone density.11,12Onthe other hand, limited in vitro and human data suggest that omeprazole may decrease bone resorption by inhibiting osteoclastic vacuolar H -K -ATPase.13-16 This study was conducted to determine whether these opposing effects of PPI therapy on bone metabolism translate into clinically important alterations in hip fracture risk in a large cohort representative of the general population.
From Jules: certain antidepressant drugs can result in bone loss look at this table:
Among the acid suppression nonusers, 10 834 incident hip fractures were identified. These fractures were added to 2722 incident hip fractures identified among the PPI users to make up the case group. These cases were matched with 135 386 controls with at least 1 eligible control to each case. The crude incidence rate of hip fracture was estimated to be 4.0/1000 person-years among patients with more than 1 year of PPI therapy and 1.8/1000 person-years among acid suppression nonusers.
The characteristics of the case and control groups appear in Table 1. The
hip fracture cases were more likely to have received medications or medical diagnoses that had known associations with either osteoporosis or the risk of falling. High BMI, hormone therapy, and long-term statin therapy were associated with reduced risk of hip fractures in crude analysis.
Controlling only for the matching variables, the crude OR for hip fracture
associated with more than 1 year of PPI therapy was 1.82 (95% CI, 1.67-2.00; P <.001), while the multivariable AOR for all the potential confounders was
1.44 (95% CI, 1.30-1.59; P .001). The corresponding AOR associated with
more than 1 year of H2RA use was 1.23 (95% CI, 1.14-1.39; P <.001). Our PPI
user group contained some users of both PPI and H2RA. To determine the effect
of PPI taken alone, PPI only users were compared with acid suppression nonusers (AOR, 1.62; 95% CI, 1.41-1.89; P <.001). In a separate secondary case-control analysis, long-term PPI therapy was associated with a higher fracture risk (AOR for >1 year of cumulative use, 1.34; 95% CI, 1.14-1.38) compared with long-term H2RA therapy (P .001).
In the regression model in which duration of PPI therapy was included as a
continuous variable, the quadratic term was significant (P <.001), suggesting that
the duration variable was associated with fracture risk in a nonlinear fashion.
Therefore, the quadratic term was included in the regression model. The strength of the association with hip fractures increased with increasing duration of PPI therapy (TABLE 2).
Among users of PPI therapy for more than 1 year, a significant dose-response
effect with respect to the average daily dose was observed (TABLE 3). The risk of hip fracture was markedly increased among long-term users of high-dose PPI therapy compared with acid suppression nonusers (AOR, 2.65;95%CI, 1.80-3.90; P< .001).
The positive association between long-term PPI therapy and hip fracture
was stronger in men (OR, 1.78; 95% CI, 1.42-2.22) than women (OR,
1.36; 95% CI, 1.22-1.53). The test for interaction between PPI therapy and sex
was statistically significant (P=.04). When the analysis was restricted to patients
with documented chronic GERD, the multivariable OR was 1.41 (95% CI, 1.02-1.94; P=.03) for hip fracture asso ciated with PPI therapy for at least 1 year,
after adjustment for age, sex, duration of follow-up, and all potential confounders
listed in Table 1. The corresponding AOR-associated with H2RA use was 1.21
(95% CI, 0.67-2.22; P=.46). A significant dose-response effect associated with
PPI therapy was again observed in this analysis restricted to patients with GERD.
The multivariable AOR associated with high-dose long-term PPI therapy was 3.49 (95% CI, 1.24-9.84; P=.02).
We found a significantly increased risk of hip fracture associated with longterm PPI therapy, particularly among long-term users of high-dose PPI. The large number of hip fracture cases in our study cohort enhanced the precision of our point estimates, and allowed adequate assessment of the effects of a comprehensive list of potential confounders. Calcium malabsorption secondary to acid suppressive therapy may potentially explain the positive association. Calcium solubility has been believed to be important for its absorption.27 An acidic environment in the gastrointestinal tract facilitates the release of ionized calcium from insoluble calcium salts.29 In rats, gastrectomy or omeprazole therapy leads to malabsorption of calcium phosphate and impaired bone mineral density.11,30 Lowering gastrointestinal pH with dietary lactate reversed the calcium malabsorption in both cases.11,30 In humans, both gastrectomy and pernicious anemia are associated with increased risk of osteopenia and fracture,31,32 although it is unclear whether achlorhydria is the primary culprit.
Furthermore, there are conflicting data regarding the importance of calcium
solubility and the role of gastric acid in intestinal calcium absorption. In individuals with normal acid secretion, insoluble calcium salts taken with or without food are absorbed at similar rates as soluble calcium salts.29 In contrast, in patients with pernicious anemia, the absorption of insoluble calcium salts taken
under fasting conditions virtually does not occur, while soluble calcium salts are
still absorbed normally.9,10 These data suggest gastric acid may be important for insoluble calcium absorption. Curiously, patients with achlorhydria can absorb
calcium carbonate, coingested with a slightly acidic meal, as efficiently as controls. 10,33 Furthermore, in a study of young healthy individuals given an
H2RA, the absorption rates of calcium carbonate coingested with a slightly
acidic meal were comparable whether the gastric pH was titrated to 7.4 or 3.0.33
This experiment casts some doubt on the importance of an acidic gastric milieu in calcium absorption. However, because the in vivo intragastric titration used is
usually carried out by measuring the pH of small aliquots of gastric content obtained every few minutes, it is uncertain whether the pH of the entire gastric
content could be maintained at a neutral level instantaneously throughout
the experiment. A study of insoluble calcium absorption in patients
with achlorhydria using a pH-neutral meal could further clarify this issue.
Gastrectomy and pernicious anemia are generally associated with much more
profound levels of acid suppression than PPI therapy. Therefore, calcium absorption data obtained from these disease models cannot be readily extrapolated to PPI therapy. A few studies have directly examined the effect of PPI therapy on calcium absorption. Among young healthy individuals, full-dose omeprazole therapy did not reduce the absorption of calcium contained in milk and cheese.34 However, in another study involving a more relevant population of women older than 65 years, omeprazole significantly reduced the absorption of calcium carbonate (an insoluble calcium salt) taken under the fasting condition. 12 It is unclear whether such malabsorption is reversible with coingestion of a meal. More studies conducted in the elderly populations using valid absorption
assays are needed to better elucidate the effect of antisecretory therapy on calcium absorption.
A considerable amount of insoluble calcium dissolves under even mildly
acidic conditions.33 One would therefore expect that profound acid suppression
(possible with high-dose PPI therapy) may be necessary to have a significant impact on calcium absorption and bone metabolism. Lower levels of acid suppression, such as those induced by regular-dose PPI therapy or H2RA
therapy, may still have a positive effect because of the significant prevalence of
Hpylori gastritis, whichmayreduce acid production, among the elderly population.
However, this effect, whether due to regular-dose PPI therapy or H2RA therapy, is likely much more modest compared with high-dose PPI therapy. This hypothesis is consistent with our observation that the increase in fracture
risk surged from a modest level with regular-dose PPI therapy to a much higher magnitude with high-dose PPI therapy.
While PPI therapy may hinder insoluble calcium absorption taken without
a meal, limited experimental data indicate that PPIs may inhibit the osteoclastic proton transport system, potentially reducing bone resorption.13-16 The irreversible proton pump inhibition by the PPIs requires a specific pH milieu. The PPIs are all prodrugs that require 2 sequential protonation steps for activation with apKa for the second step of less than 1.35 As a result, the proton pump inhibition action of the PPIs is extremely site-specific. In addition to the secretory canaliculi of the gastric parietal cells, the osteoclastic resorption vacuole may be the only other place in which proton pumpinhibition by PPIs is known to take place. Our results would suggest that it is possible that the potentially protective effect of osteoclastic proton pump inhibition may have canceled out some of the negative effects of gastric acid suppression by PPIs, especially at regular doses, potentially leading to overlap between the effect of low-dose PPIs and H2RAs. However, with high-dose PPI therapy, the effect of gastric acid suppression dominated.
Our findings are consistent to some extent with a recent case-control study
conducted in a Danish population by Vestergaard et al,36 which showed that
recent PPI therapy was associated with an increased risk of hip fractures (OR,
1.45; 95% CI, 1.28-1.65). However, in contrast to our study, Vestergaard et al
observed neither a duration-response nor a dose-response effect associated
with PPI therapy. The discrepancy is probably due to differences in study design.
The maximum follow-up and duration of potential PPI exposure in our cohort were close to 15 years (1988-2003) compared with 5 years (1996- 2000) in the study by Vestergaard et al.36 As such, our study may be less susceptible to the influence of left censoring and thus better able to capture the effect of long-term PPI therapy. In fact, duration of PPI use was indirectly measured by cumulated number of daily defined doses (ie, a standardized daily dose unit) in the study by Vestergaard et al, and the longest duration category was more than 3 months in their study compared with 4 years in our study. In addition, while we assessed
the presence of a dose-response effect associated with PPI therapy among
long-term (ie, 1 year) users only, Vestergaard et al36 analyzed the dosage effect among PPI users of any duration, including those with minimal duration of total PPI exposure. Because short-term PPI use is unlikely to have a significant impact on fracture risk regardless of how high the daily dosage, a positive dose-response effect may only be demonstrable among long term PPI users.
In addition, the daily dosage variable in the study by Vestergaard et al36
was defined by dividing the cumulative daily defined doses of PPI used during
the last year of follow-up by the number of days from first PPI use in the last year to the index date. Based on this definition, even the highest daily dosage
category ( 1 defined dose per day) could theoretically include patients receiving
once daily PPI exclusively, while the lower dosage categories could include those receiving a double daily dose of PPI therapy exclusively. Therefore, in contrast to our study, this daily dosage variable in the Danish study was not designed to capture the variation in the extent of acid suppression due to different PPI daily dosages during the periods of active therapy, which may be the crucial factor in this context based on our data. In fact, Vestergaard et al36 indicated that this variable was defined as such to account for the expected intermittency of PPI use.
As with all observational studies of the effects of medications, the potential
for confounding by indication should be carefully assessed. Patients with comorbidities may be more likely to be prescribed acid suppressive
therapy. These patients also may be more likely to experience hip fracture due to factors such as decreased weightbearing activities, poor nutrition, increased
fall risk, and decreased sunlight exposure. In this study, we controlled for comorbidity status primarily through the inclusion of a comprehensive list of relevant variables in the regression model.
Residual confounding by unmeasured factors is always possible in an
observational study. However, such confounding would not only have to be
of considerable magnitude but also be substantially independent of the comprehensive list of factors already included to negate the positive association
observed in this study in general and the marked risk increase among high-dose PPI users in particular.
Furthermore, we conducted an additional analysis restricted to patients
who had documented chronic GERD. What we were interested in learning
from this analysis was whether there was a significant change in the point estimate between this analysis and the primary analysis. At the very least, the PPI users in this restricted analysis were much more likely to have received PPI
for GERD than a mixed group of PPI users with or without a GERD diagnosis.
Therefore, to the extent that confounding by indication is present in the primary analysis, its effect should be less in a comparison between PPI users with
GERD and PPI nonusers with GERD than in a comparison between all PPI
users and all PPI nonusers. The fact that the point estimate changed negligibly
between these 2 analyses suggested that residual confounding by indication was
unlikely to be a major source of bias in our primary analysis. This analysis also
largely excluded the possibility that GERD itself may be responsible for the
increase in hip fracture risk.
Several other limitations also warrant consideration. Ourstudy was not designed
to define the specific mechanism(s) underlying the association between PPI therapy and the risk of fracture. As a result, while the dose-response effect observed could be explained by a mechanism mediated by gastric acid suppression, we cannot be certain that there are no alternative explanations for the different effects associated with regular-dose and high-dose
PPI therapy. In addition, in our cohort, the BMI was missing for 33% of the patients. We conducted a restriction analysis limited to those patients with BMI information recorded. The results of this analysis were nearly identical to the
analyses in which those with missing BMI information were placed in a separate
category of "unknown" (data not shown). Furthermore, inclusion of BMI
information in the regression model generally increased strength of the positive
association between PPI use and fracture risk in these analyses. Thus, it seems
unlikely that the observed association between long-term PPI use and fracture risk is due to incomplete adjustment for BMI. We could not capture PPI use prior
to patient enrollment in the database. Therefore, we could have underestimated
the duration of exposure. However, this should have created bias against observing a trend for a stronger association with longer duration of therapy. That we observed such an association argues against this form of bias having led to the wrong conclusions.
Finally, we were unable to fully determine whether receiving calcium supplementation influenced the primary association because we did not
have information on over-the-counter calcium supplement use. We observed
significant modification of the primary effect by sex among long-term PPI users. While this phenomenon may be due to other sex-related factors involved in the pathogenesis of osteoporosis, future studies should assess whether a higher prevalence of calcium supplement use among women compared with men played a role.37
In summary, we observed that PPI therapy is associated with a significantly
increased risk of hip fractures, with the highest risk seen among those receiving high-dose PPI therapy. Osteoporotic fractures are common among the elderly population, and they entail considerable morbidity and mortality. On the other hand, PPI therapy is widespread and may have an exaggerated effect among those at risk for osteoporosis.
Thus, further studies are urgently needed to confirm our findings and
clarify the underlying mechanism. At this point, physicians should be aware of this potential association when considering PPI therapy and should use the lowest effective dose for patients with appropriate indications. For elderly patients
who require long-term and particularly high-dose PPI therapy, it may be prudent
to reemphasize increased calcium intake, preferably from a dairy source, and coingestion of a meal when taking insoluble calcium supplements.